A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors. - Ku G; Shen L; Dayyani F; Kratz J; Liang X; Liu F; Wang Z; Feller L; Girda E; Pan H; Kim S; Deng Y; et al. (Clinical cancer research : an official journal of the American Association for Cancer Research, 2025)